Recently, VU661013, a new Mcl-1-specific inhibitor, has been reported to rescue venetoclax resistance in AML [159] and inhibit cell survival in estrogen receptor-positive breast cancer when used in combination with navitoclax [160]. Here, MCL1 is linked to breast carcinoma.